Quick Summary
Evergraf 0.5mg Tablet
Last updated on 06 Jun 2026 | 04:51 AM (IST)
₹1256
MRP: ₹1570.96
(You Save ₹314.96)
10 TABLET(s) IN A STRIP
20% OFF
₹1256
MRP: ₹1,570.96
Inclusive of all taxes
20% Off
Dispatch: Today
Order In: 0h 0m 0s
0h 0m 0s
Order before timer ends to ensure your medicine is dispatched at...
Substitutes
Lanolimus 0.5mg Tablet
MYLAN PHARMACEU...
₹ 55.20/tablet
56% cheaper
Evercon 0.5mg Tablet
CONCORD BIOTECH...
₹ 65.80/tablet
47% cheaper
Suregraft 0.50mg Tablet
HOSPIMAX HEALTH...
₹ 78.90/tablet
37% cheaper
Advacan 0.5mg Tablet
ERIS LIFESCIENC...
₹ 87.60/tablet
30% cheaper
Introduction
Evergraf 0.5mg Tablet is an antineoplastic drug belonging to the class of mTOR kinase inhibitors, containing the active ingredient everolimus. It is commonly prescribed for advanced breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumours, and in the treatment of subependymal giant cell astrocytoma (tumours found in the ventricles of the brain). It is also used in certain cases of kidney transplant and other cancers. Good oral hygiene and regular dental check-ups are important during treatment since this medicine may cause sores or ulcers in the mouth. In some cases, it is combined with cyclophosphamide, an alkylating agent, to manage subependymal giant cell astrocytoma.
The evergraf 0.5mg dosage must be followed exactly as prescribed by your healthcare provider. Before starting the treatment, it is important to understand that your risk of bacterial or viral infections increases. If you have a history of Hepatitis B, Evergraf 0.5mg Tablet may increase the chances of reinfection. Inform your healthcare provider immediately if you experience fever, chills, cough, yellowing of the skin, joint pain, or swelling.
Patients are advised to limit exposure to sunlight and UV light by wearing protective clothing and using sunscreen regularly, as Evergraf can increase the risk of developing skin cancers. Avoid grapefruit juice or grapefruit during treatment, as it can affect how the drug works.
For patients comparing treatment options, evergraf 0.5mg substitute medicines may be considered if advised by the doctor. Information regarding evergraf 0.5mg price, evergraf 0.5mg for cancer, and evergraf 0.5mg for kidney transplant should be discussed with your healthcare provider or pharmacist for proper guidance. You may also review evergraf 0.5mg tablet substitutes if recommended in your treatment plan.
Uses
Evergraf 0.5mg uses are
- Advanced breast cancer
- Advanced renal cell carcinoma
- Advanced pancreatic neuroendocrine tumours
- Treatment of subependymal giant cell astrocytoma
How Evergraf 0.5mg Tablet works
Evergraf 0.5mg tablet inhibits the activity of a protein called mammalian target of rapamycin (mTOR), which regulates cell growth. This drug can slow the growth of abnormal cancer cells by blocking the mTOR protein and helps to reduce the size of tumours and improve outcomes in patients.
Interaction of Evergraf 0.5mg Tablet with other drugs
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Evergraf 0.5mg tablet and reduce effectiveness by causing undesirable side effects.
Storage conditions
- Store Evergraf 0.5mg tablet in the original package at room temperature (20°C to 25°C).
- Keep it out of reach from children.
How to take Evergraf 0.5mg Tablet
Take the Evergraf 0.5mg tablet as advised by your physician. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.
Safety Advice for Evergraf 0.5mg Tablet
Breast Feeding
Evergraf 0.5mg Tablet passes into your breast milk and harms your baby. It is unsafe to consume this tablet.
Alcohol
Consuming alcohol may affect the effectiveness of Evergraf 0.5mg tablet. Stop consuming alcohol if you are taking this medicine.
Liver
Inform your doctor if you have any liver problems before taking Evergraf 0.5mg tablet. Regular monitoring of liver function tests is recommended.
Lungs
It is not known whether Evergraf 0.5mg tablet can be used for patients with lung problems. Consult your doctor if you have any lung diseases before starting the treatment.
Driving
It is unsafe to drive vehicles or operate heavy machinery after taking Evergraf 0.5mg tablet, it may cause dizziness and impair your concentration.
Pregnancy
Evergraf 0.5mg tablet is not recommended for pregnant women as it may cause fetal harm. Consult your doctor if you are pregnant or planning for pregnancy during the treatment.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Evergraf 0.5mg side effects are
Serious
- Difficulty breathing, or swallowing
- Swelling of face, lips, tongue, throat
- Severe itching, red rash, raised bumps
Common
- Infection (chills, increased temperature)
- Coughing
- Wheezing
- Excessive thirst
- High urine output or severely decreased urine output
- Tiredness
- Bleeding
- Increased appetite with weight loss
Expert Tips
-
Risk to pregnancy: Evergraf 0.5mg Tablet may harm the unborn fetus. Inform your healthcare provider if you are pregnant or planning pregnancy.
-
Pregnancy testing: A pregnancy test will be conducted before starting treatment.
-
Birth control: Discuss effective contraceptive methods with your doctor and use them during treatment and for 8 weeks after your last dose.
-
Breastfeeding caution: The medicine passes into breast milk, so breastfeeding is not recommended during treatment.
-
Mouth ulcers: Occurrence of mouth ulcers or sores is common during this treatment.
-
Mouthwash use: Your healthcare provider may prescribe a mouthwash—use it as recommended to prevent and manage these symptoms.
FAQs about Evergraf 0.5mg Tablet
Q1.
What you should know before taking Evergraf 0.5mg tablet?
Before taking Evergraf 0.5mg tablet, it is important to know that your risk of getting bacterial or viral infection increases with this treatment. If you have been infected with Hepatitis B, this drug increases the chances of reinfection. Tell your healthcare provider if you experience fever, chills, cough, yellowing of the skin, joint pain, or swelling during this treatment.
Q2.
Is it safe to use Evergraf 0.5mg tablet during pregnancy?
Evergraf 0.5mg tablet has the tendency to cause harm to the unborn fetus. Inform your healthcare provider before starting this treatment if you are pregnant, or planning for pregnancy. Your healthcare provider will conduct a pregnancy test before you start treatment with this drug.
Q3.
What are the side effects of Evergraf 0.5mg Tablet?
The common side effects that are likely to occur while you are on the treatment with Evergraf 0.5mg tablet are fever, chills, skin rash, joint pain, swelling, tiredness, loss of appetite, high risk of infection, mouth ulcers, and difficulty breathing.
Q4.
Is it safe to undergo surgery while on treatment with Evergraf 0.5mg tablet?
Evergraf 0.5mg tablet may lead to poor wound healing ability. Consult your healthcare provider and stop taking this tablet at least one week before planned surgery.
Q5.
Can I drink alcohol while taking Evergraf 0.5mg tablet?
It is generally recommended to avoid drinking alcohol while taking Evergraf 0.5mg tablet, as alcohol can increase the risk of liver damage.
Fact Box of Evergraf 0.5mg Tablet
|
Molecule name
|
Everolimus |
|
Therapeutic class |
Antineoplastics |
|
Pharmacological class |
mTOR kinase inhibitors |
|
Indications |
1. Advanced breast cancer 2. Advanced renal cell carcinoma 3. Advanced pancreatic neuroendocrine tumors 4. Treatment of subependymal giant cell astrocytoma |
References
- Novartis Pharmaceuticals UK Limited, Electronic medicines compendium (EMC), [ Revised on June 2022] [ Accessed on 18th March 2023], https://www.medicines.org.uk/emc/files/pil.6658.pdf
- Jan Hasskarl; Everolimus; Recent Results in Cancer Research; Published on 2018; Accessed on 18/03/2023; https://pubmed.ncbi.nlm.nih.gov/30069763/
- Novartis Pharmaceuticals Corporation, US Food and Drug Administration, [ Revised on July 2012] [ Accessed on 18th March 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf
- Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Targeted therapy: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines, 12th edition, 2011, 1743.
- KD Tripathi, Essentials of Medical Pharmacology, Immunosuppressant drugs, 7th edition, 2013, 878 - 882.
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
Did you find this information helpful?
Author Details
Written By
Dr. B. Deiva
Pharm D
Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 06 Jun 2026 | 04:51 AM (IST)
Want to know more?
Read Our Editorial Policy
